Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Michael Grever; Leslie Andritsos; Versha Banerji; Jacqueline C. Barrientos; Seema Bhat; James S. Blachly; Timothy Call; Matthew Cross; Claire Dearden; Judit Demeter; Sasha Dietrich; Brunangelo Falini; Francesco Forconi; Douglas E. Gladstone; Alessandro Gozzetti; Sunil Iyengar; James B. Johnston; Gunnar Juliusson; Eric Kraut; Robert J. Kreitman; Francesco Lauria; Gerard Lozanski; Sameer A. Parikh; Jae Park; Aaron Polliack; Farhad Ravandi; Tadeusz Robak; Kerry A. Rogers; Alan Saven; John F. Seymour; Tamar Tadmor; Martin S. Tallman; Constantine S. Tam; Enrico Tiacci; Xavier Troussard; Clive Zent; Thorsten Zenz; Pier Luigi Zinzani; Bernhard Wörmann

doi:10.1038/s41375-021-01257-7

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Michael Grever, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema Bhat, James S. Blachly, Timothy Call, Matthew Cross, Claire Dearden, Judit Demeter, Sasha Dietrich, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Gunnar Juliusson, Eric Kraut, Robert J. KreitmanFrancesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae Park, Aaron Polliack, Farhad Ravandi, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Clive Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann

Hematology

Research output: Contribution to journal › Review article › peer-review

Abstract

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

Original language	English (US)
Pages (from-to)	1864-1872
Number of pages	9
Journal	Leukemia
Volume	35
Issue number	7
DOIs	https://doi.org/10.1038/s41375-021-01257-7
State	Published - Jul 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01257-7

Cite this

Grever, M., Andritsos, L., Banerji, V., Barrientos, J. C., Bhat, S., Blachly, J. S., Call, T., Cross, M., Dearden, C., Demeter, J., Dietrich, S., Falini, B., Forconi, F., Gladstone, D. E., Gozzetti, A., Iyengar, S., Johnston, J. B., Juliusson, G., Kraut, E., ... Wörmann, B. (2021). Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 35(7), 1864-1872. https://doi.org/10.1038/s41375-021-01257-7

Grever, M, Andritsos, L, Banerji, V, Barrientos, JC, Bhat, S, Blachly, JS, Call, T, Cross, M, Dearden, C, Demeter, J, Dietrich, S, Falini, B, Forconi, F, Gladstone, DE, Gozzetti, A, Iyengar, S, Johnston, JB, Juliusson, G, Kraut, E, Kreitman, RJ, Lauria, F, Lozanski, G, Parikh, SA, Park, J, Polliack, A, Ravandi, F, Robak, T, Rogers, KA, Saven, A, Seymour, JF, Tadmor, T, Tallman, MS, Tam, CS, Tiacci, E, Troussard, X, Zent, C, Zenz, T, Zinzani, PL & Wörmann, B 2021, 'Hairy cell leukemia and COVID-19 adaptation of treatment guidelines', Leukemia, vol. 35, no. 7, pp. 1864-1872. https://doi.org/10.1038/s41375-021-01257-7

@article{d073d3863f6c4d389a43ab82b3313acc,

title = "Hairy cell leukemia and COVID-19 adaptation of treatment guidelines",

abstract = "Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.",

author = "Michael Grever and Leslie Andritsos and Versha Banerji and Barrientos, {Jacqueline C.} and Seema Bhat and Blachly, {James S.} and Timothy Call and Matthew Cross and Claire Dearden and Judit Demeter and Sasha Dietrich and Brunangelo Falini and Francesco Forconi and Gladstone, {Douglas E.} and Alessandro Gozzetti and Sunil Iyengar and Johnston, {James B.} and Gunnar Juliusson and Eric Kraut and Kreitman, {Robert J.} and Francesco Lauria and Gerard Lozanski and Parikh, {Sameer A.} and Jae Park and Aaron Polliack and Farhad Ravandi and Tadeusz Robak and Rogers, {Kerry A.} and Alan Saven and Seymour, {John F.} and Tamar Tadmor and Tallman, {Martin S.} and Tam, {Constantine S.} and Enrico Tiacci and Xavier Troussard and Clive Zent and Thorsten Zenz and Zinzani, {Pier Luigi} and Bernhard W{\"o}rmann",

note = "Funding Information: Conflict of interest LA: previously provided consultation services for Innate Pharma and AstraZeneca. VB: VB serves on the Advisory Boards of Gilead, Lundbeck, Janssen, AstraZeneca, and Abbvie and has had research funding from CIHR, LLSC, CCMF, Roche, Janssen, Abbvie, and Lundbeck. VB also received fees from BIOGEN for patented compounds unrelated to this study. JCB: research funding: AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/AbbVie; Advisory Board: AstraZeneca, Pharmacyclics/Abbvie, Beigene, Gen-entech, Gilead, Innate. SB: served on Advisory board for Pharma-cyclics and Janssen, Beigene and AstraZeneca; received honorarium from OncLive; received travel grant from Arqule. JSB: consulting and Advisory Board: AbbVie, AstraZeneca, INNATE Pharma, KITE Pharma; research funding: MingSight Pharmaceuticals: patents and intellectual property: a leukemia diagnostic device (patent pending). Research work is funded by the Royal Marden Cancer Charity. CD: has been an advisor for Medimmune/Innate Pharma (moxetumomab); consulting/Advisory Board for Abbie and Jansen. JD: has participated in advisory committees in Hungary for Novartis, Bristol Myers Squibb, Amicus, Angelini, Pfizer, Amgen, Roche. AG: Advisory Board: Amgen, Takeda. Research funding: Jansenn and Cilag SPA. Honoraria: Abbvie, Jansenn Cilag, Celgene, Amgen, Takeda. Michael Grever: consultant: AstraZeneca, Pharmacyclics, Ascerta, Axio, Inc. Research funding: Hairy Cell Leukemia Foundation for Patient Data Registry; travel expenses: Hairy Cell Leukemia Foundation; Scientific Board Chair: Hairy Cell Leukemia Foundation Scientific Board (no reimbursement); Scientific Honorarium: University of Pittsburgh. SI: Advisory and speaker fees: Gilead and Takeda; Advisory: Beigene; Speaker fees: Janssen, Takeda, and Gilead. RJK: employment: National Institutes of Health and Regional Cancer Care Associates; Honoraria: PlatformQ, OncLive, Cure; research funding: Innate, AstraZeneca, Novartis, Genetech, Pfizer, Teva, Hairy Cell Leukemia Foundation; patents: coinventor for NIH patent for Moxetumomab Pasudotox. SAP: research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithK-line, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). JP: research funding from Genentech, Servier, Takeda, Fate Therapeutics, and Amgen. Consulting fees from Servier, Amgen, AstraZeneca, Innate Pharma, Novartis, Kite Pharma, Takeda, Intellia, and Kura Oncology. FR: Consultancy and Honoraria—Celgene, BMS, Amgen, Astellas, Xen-cor, Agios, AstraZeneca, Orsenix, Innate Pharma, Syros, Taiho, Novartis; research funding—BMS, Amgen, Xencor, Macrogenics, Orsenix, Abbvie, Taiho, Prelude, Astex. TR: research funding: AstraZeneca, Medimmune, Roche, Janssen, Abbvie, Advisory Board; AstraZeneca, Jassen, Abbvie; travel grant: Roche, Janssen; Honoraria: Abbvie, AstraZeneca, Janssen. KAR: received research funding from Genentech, AbbVie, Janssen, and Novartis all paid to her institution, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, Genentech, AbbVie, and Pharmacyclics, received travel funding from AstraZe-neca. AS: consultant and Advisory Boards: AstraZeneca and Innate Pharmaceuticals; Speakers Bureau: AbbVie and Pharmacyclics. JFS: AbbVie, Advisory board, speakers{\textquoteright} bureau, research funding; Astra-Zeneca, Advisory board; Celgene, Advisory board, speakers{\textquoteright} bureau, research funding, expert testimony; Genentech, Advisory board; Gilead, Advisory Board; Janssen, Advisory board, research funding; Mei Pharma, Advisory board; Morphosys, Advisory Board; Roche, Advisory board, speakers{\textquoteright} bureau, research funding, expert testimony; Sunesis, Advisory board; Takeda, Advisory Board. TT: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca, Novartis. MST: research funding: AbbVie, Amgen, Biosight, Glycomimetics, Orsenix, Rafael; Advisory Boards: Amgen, Daiichi-Sankyo, Delta Fly Pharma, Innate pharmaceuticals, Jazz, Kahr, Kura, Novartis, Orsenix, Roche, Syros; Royalties: UpToDate. CST: Honoraria from Janssen, AbbVie and Beigene, and his hospital receives research funding from Janssen, AbbVie, and Beigene. ET: consultant for Innate Pharma. Research funding: Roche. Travel cost: Shire. Holder of a patent on the use of mutant BRAF as HCL biomarker. Our research work in HCL is funded by the Hairy Cell Leukemia Foundation, the Leukemia and Lymphoma Society, and the Associazione Italiana Ricerca sul Cancro (AIRC). XT: consultant for Innate Pharma, AstraZeneca; advisor: Abbvie. Clive Zent: funding through the University of Rochester for laboratory research, from Acerta/AstraZeneca and TG Therapeutics, and from the Hairy Cell Leukemia Foundation. TZ: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca. PLZ: Speakers Bureau: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin; Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin, ADC Therap.; consultant: Verastem, MSD, Eusa-pharma, Sanofi. The other authors declare no competing interests. Funding Information: Acknowledgements This work was supported by the Hairy Cell Foundation. Administrative support was provided by its executive director Anna Lambertson. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = jul,

doi = "10.1038/s41375-021-01257-7",

language = "English (US)",

volume = "35",

pages = "1864--1872",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

AU - Grever, Michael

AU - Andritsos, Leslie

AU - Banerji, Versha

AU - Barrientos, Jacqueline C.

AU - Bhat, Seema

AU - Blachly, James S.

AU - Call, Timothy

AU - Cross, Matthew

AU - Dearden, Claire

AU - Demeter, Judit

AU - Dietrich, Sasha

AU - Falini, Brunangelo

AU - Forconi, Francesco

AU - Gladstone, Douglas E.

AU - Gozzetti, Alessandro

AU - Iyengar, Sunil

AU - Johnston, James B.

AU - Juliusson, Gunnar

AU - Kraut, Eric

AU - Kreitman, Robert J.

AU - Lauria, Francesco

AU - Lozanski, Gerard

AU - Parikh, Sameer A.

AU - Park, Jae

AU - Polliack, Aaron

AU - Ravandi, Farhad

AU - Robak, Tadeusz

AU - Rogers, Kerry A.

AU - Saven, Alan

AU - Seymour, John F.

AU - Tadmor, Tamar

AU - Tallman, Martin S.

AU - Tam, Constantine S.

AU - Tiacci, Enrico

AU - Troussard, Xavier

AU - Zent, Clive

AU - Zenz, Thorsten

AU - Zinzani, Pier Luigi

AU - Wörmann, Bernhard

N1 - Funding Information: Conflict of interest LA: previously provided consultation services for Innate Pharma and AstraZeneca. VB: VB serves on the Advisory Boards of Gilead, Lundbeck, Janssen, AstraZeneca, and Abbvie and has had research funding from CIHR, LLSC, CCMF, Roche, Janssen, Abbvie, and Lundbeck. VB also received fees from BIOGEN for patented compounds unrelated to this study. JCB: research funding: AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/AbbVie; Advisory Board: AstraZeneca, Pharmacyclics/Abbvie, Beigene, Gen-entech, Gilead, Innate. SB: served on Advisory board for Pharma-cyclics and Janssen, Beigene and AstraZeneca; received honorarium from OncLive; received travel grant from Arqule. JSB: consulting and Advisory Board: AbbVie, AstraZeneca, INNATE Pharma, KITE Pharma; research funding: MingSight Pharmaceuticals: patents and intellectual property: a leukemia diagnostic device (patent pending). Research work is funded by the Royal Marden Cancer Charity. CD: has been an advisor for Medimmune/Innate Pharma (moxetumomab); consulting/Advisory Board for Abbie and Jansen. JD: has participated in advisory committees in Hungary for Novartis, Bristol Myers Squibb, Amicus, Angelini, Pfizer, Amgen, Roche. AG: Advisory Board: Amgen, Takeda. Research funding: Jansenn and Cilag SPA. Honoraria: Abbvie, Jansenn Cilag, Celgene, Amgen, Takeda. Michael Grever: consultant: AstraZeneca, Pharmacyclics, Ascerta, Axio, Inc. Research funding: Hairy Cell Leukemia Foundation for Patient Data Registry; travel expenses: Hairy Cell Leukemia Foundation; Scientific Board Chair: Hairy Cell Leukemia Foundation Scientific Board (no reimbursement); Scientific Honorarium: University of Pittsburgh. SI: Advisory and speaker fees: Gilead and Takeda; Advisory: Beigene; Speaker fees: Janssen, Takeda, and Gilead. RJK: employment: National Institutes of Health and Regional Cancer Care Associates; Honoraria: PlatformQ, OncLive, Cure; research funding: Innate, AstraZeneca, Novartis, Genetech, Pfizer, Teva, Hairy Cell Leukemia Foundation; patents: coinventor for NIH patent for Moxetumomab Pasudotox. SAP: research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithK-line, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). JP: research funding from Genentech, Servier, Takeda, Fate Therapeutics, and Amgen. Consulting fees from Servier, Amgen, AstraZeneca, Innate Pharma, Novartis, Kite Pharma, Takeda, Intellia, and Kura Oncology. FR: Consultancy and Honoraria—Celgene, BMS, Amgen, Astellas, Xen-cor, Agios, AstraZeneca, Orsenix, Innate Pharma, Syros, Taiho, Novartis; research funding—BMS, Amgen, Xencor, Macrogenics, Orsenix, Abbvie, Taiho, Prelude, Astex. TR: research funding: AstraZeneca, Medimmune, Roche, Janssen, Abbvie, Advisory Board; AstraZeneca, Jassen, Abbvie; travel grant: Roche, Janssen; Honoraria: Abbvie, AstraZeneca, Janssen. KAR: received research funding from Genentech, AbbVie, Janssen, and Novartis all paid to her institution, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, Genentech, AbbVie, and Pharmacyclics, received travel funding from AstraZe-neca. AS: consultant and Advisory Boards: AstraZeneca and Innate Pharmaceuticals; Speakers Bureau: AbbVie and Pharmacyclics. JFS: AbbVie, Advisory board, speakers’ bureau, research funding; Astra-Zeneca, Advisory board; Celgene, Advisory board, speakers’ bureau, research funding, expert testimony; Genentech, Advisory board; Gilead, Advisory Board; Janssen, Advisory board, research funding; Mei Pharma, Advisory board; Morphosys, Advisory Board; Roche, Advisory board, speakers’ bureau, research funding, expert testimony; Sunesis, Advisory board; Takeda, Advisory Board. TT: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca, Novartis. MST: research funding: AbbVie, Amgen, Biosight, Glycomimetics, Orsenix, Rafael; Advisory Boards: Amgen, Daiichi-Sankyo, Delta Fly Pharma, Innate pharmaceuticals, Jazz, Kahr, Kura, Novartis, Orsenix, Roche, Syros; Royalties: UpToDate. CST: Honoraria from Janssen, AbbVie and Beigene, and his hospital receives research funding from Janssen, AbbVie, and Beigene. ET: consultant for Innate Pharma. Research funding: Roche. Travel cost: Shire. Holder of a patent on the use of mutant BRAF as HCL biomarker. Our research work in HCL is funded by the Hairy Cell Leukemia Foundation, the Leukemia and Lymphoma Society, and the Associazione Italiana Ricerca sul Cancro (AIRC). XT: consultant for Innate Pharma, AstraZeneca; advisor: Abbvie. Clive Zent: funding through the University of Rochester for laboratory research, from Acerta/AstraZeneca and TG Therapeutics, and from the Hairy Cell Leukemia Foundation. TZ: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca. PLZ: Speakers Bureau: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin; Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin, ADC Therap.; consultant: Verastem, MSD, Eusa-pharma, Sanofi. The other authors declare no competing interests. Funding Information: Acknowledgements This work was supported by the Hairy Cell Foundation. Administrative support was provided by its executive director Anna Lambertson. Publisher Copyright: © 2021, The Author(s).

PY - 2021/7

Y1 - 2021/7

N2 - Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

AB - Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85105316132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105316132&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01257-7

DO - 10.1038/s41375-021-01257-7

M3 - Review article

C2 - 33947938

AN - SCOPUS:85105316132

SN - 0887-6924

VL - 35

SP - 1864

EP - 1872

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this